Skip to content
AnecdotalNootropic peptide blend for cognition and mood

Adamax

Also indexed as Adamax Peptide Blend, BPC-157 + Adamax Complex

Adamax is a research peptide blend reported to combine nootropic and neuroprotective peptide components aimed at enhancing cognitive function, mood stability, and neural recovery. It is marketed primarily for its potential effects on dopaminergic and serotonergic signaling pathways. Evidence is largely limited to preclinical and anecdotal sources, with no published human clinical trials specific to the Adamax formulation.

Overview

Following subcutaneous or intramuscular administration, peptide components are absorbed into systemic circulation with estimated bioavailability dependent on molecular size and enzymatic stability. Smaller peptide fragments may cross the blood-brain barrier via specific transport mechanisms (e.g., peptide transporter PEPT2) or by transcytosis. Distribution to CNS targets — including hippocampus, prefrontal cortex, and amygdala — likely occurs within 30–90 minutes. Hepatic degradation and renal clearance are the primary elimination routes, with an estimated half-life of 2–4 hours based on analogous peptides. No published pharmacokinetic studies specific to Adamax exist.

Proposed mechanism

Adamax is believed to act on central nervous system neurotransmitter systems, potentially modulating dopamine and serotonin receptor activity to support cognitive clarity and mood regulation. The peptide components may also exert neuroprotective effects by reducing neuroinflammation and supporting synaptic plasticity. Some constituent peptides in similar blends have shown interaction with BDNF (brain-derived neurotrophic factor) pathways in animal models, which may underlie reported cognitive benefits.

What the evidence supports

Evidence rests primarily on self-reported experience. Controlled studies are lacking.

Graded Anecdotal

Case reports, clinician notes, and user-reported outcomes. Recorded for completeness and labelled plainly so it is never mistaken for data.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Semax and its analogs: Neuroprotective and nootropic properties

    · Journal of Neurochemistry (mechanistic background for ACTH-fragment peptides) · 2017

  2. [2]

    Brain-derived neurotrophic factor and its clinical implications

    · Acta Neurologica Scandinavica — doi:10.1111/ane.12225 · 2014

  3. [3]

    Selank modulates the expression of interleukins and serotonin metabolism

    · Bulletin of Experimental Biology and Medicine (general mechanistic analogy) · 2012

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

ACTH 1-39

Clinical

Full-length adrenal hormone with broad receptor activity

ACTH 1-39 is the full-length, biologically active form of adrenocorticotropic hormone, a 39-amino acid peptide naturally secreted by the anterior pituitary gland. It primarily stimulates the adrenal cortex to produce cortisol, aldosterone, and adrenal androgens. Beyond adrenal signaling, ACTH 1-39 exerts direct effects on the brain, immune system, and peripheral tissues via melanocortin receptors.

0 RCT · 0 human · 0 preclinical

Immune

ARA290 (Cibinetide)

Human-limited

Tissue-protective peptide for nerve repair and inflammation

ARA290, also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the helix B surface peptide of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis. It is designed to harness the tissue-protective and anti-inflammatory properties of EPO while avoiding its hematopoietic side effects. Clinically, it has been investigated for neuropathic pain, small fiber neuropathy, and inflammatory conditions such as sarcoidosis.

0 RCT · 0 human · 0 preclinical

Immune

B7-33

Animal

Biased RXFP1 agonist for cardiac fibrosis

B7-33 is a single-chain peptide analog of human relaxin-2, engineered to selectively activate the RXFP1 receptor without triggering the cAMP signaling pathway. It demonstrates potent anti-fibrotic, vasodilatory, and cardioprotective effects in preclinical models. Research primarily focuses on its potential in heart failure, pulmonary arterial hypertension, and organ fibrosis.

0 RCT · 0 human · 0 preclinical

Cardiovascular